The Latest Breaking News from Insulet

Neurocrine Biosciences leads five medical stocks near key support levels as the health care sector shows resilience in a sickly market.

Several stocks flashed buy signals as the market rallied heading into Fed chief Powell's speech. Here's what to expect.

The U.S. Food and Drug Administration (FDA) has announced clearance to Insulet’s (NASDAQ:PODD) Omnipod 5 Automated Insulin Delivery System (Omnipod 5) for individuals aged two years and older with type 1 diabetes (T1D). Insulet shares traded in a range of $260.13 to $266.73 on day volume of 200.86 thousand shares…

Futures fell sharply as the market rally pulls back. Elon Musk will hike Tesla FSD prices. Warren Buffett stock Occidental Petroleum surged Friday.

Insulet is the IBD Stock Of The Day as excitement around the company's new insulin pump, Omnipod 5, drives PODD stock closer to a breakout.

Upgrades

Insulet (NASDAQ:PODD) has observed the following analyst ratings within the last quarter:

Analysts have provided the following ratings for Insulet (NASDAQ:PODD) within the last quarter:

Dexcom stock popped Tuesday after the diabetes devices company refuted rumors that it's in active negotiations to acquire any company.

According to Benzinga Pro, during Q1, Insulet (NASDAQ:PODD) earned $27.80 million, a 4.79% increase from the preceding quarter. Insulet's sales decreased to $295.40 million, a 4.0% change since Q4.

Dexcom stock yo-yoed Wednesday after a Tuesday dive on rumors it's in talks to acquire insulin pump-maker Insulet in a major diabetes deal.